Agilent Technologies Inc (A) Fair Value & Analysis

Healthcare · US · Market cap $37.1B · ISIN US00846U1016

What is Agilent Technologies Inc really worth?

Agilent Technologies Inc A · US

Price$149.98

Fair Value$61.53

Upside−59.0%

Quality70/100

A solid business, but trading 144% above our fair value of $61.53.

Watch Agilent Technologies Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +5.4 %/yr)

✓Solidly profitable · 19.6% net margin

✓Low debt · generates free cash flow

✓Wide moat 78/100

Risks

!Mixed vs. peers (8/15)

!Weak on dividend: 13 out of 100

For context

·0.67% dividend yield

Evidence: High Range $40.81 – $102.54

Fair value as of: Sep 3, 2026

From 24 valuation models · updated yesterday

Share price +7.7% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
The price sits above even our optimistic bull case ($102.54). The favourable scenario is already priced in.
A fairly wide model range ($40.81 to $102.54) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 3, 2026.

How to read this chart

60‑month range $98.29 – $173.03 · fair‑value band $40.81 – $102.54 · the $149.98 price screens above the $61.53 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 3, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Agilent Technologies Inc (A) currently trades at $149.98, while our model-based Fair Value estimate is $61.53, implying the stock looks roughly 143.7% overvalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $78.87 per share, and 0 of the 24 models we run sit above the $149.98 price. Bear case: the Dividend Discount group reads lowest at $12.95, and 24 of the 24 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Agilent Technologies Inc generated revenue of $7.2B at a net margin of 19.6%. Revenue grew 10.0% year over year. It earns a return on equity of 21.3%. Net debt stands at $1.6B. Fundamentals as of Sep 3, 2026

Our scenario range runs from $40.81 (bear case) to $102.54 (bull case); at $149.98, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 6% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −52% fair-value upside, at −59%, A screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 10 months have passed since. In that time the company retained roughly $3.22 per share, which is 5.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

FCF DCF $37.87 $54.76 $79.56 80

Growth DCF $39.32 $55.39 $77.96 79

Owner Earnings $39.04 $56.41 $81.89 76

All 24 models by family

DCF Models

FCF DCF $37.87 $54.76 $79.56 80

Owner Earnings $39.04 $56.41 $81.89 76

5Y Revenue Exit $39.17 $61.04 $88.46 72

5Y EBITDA Exit $47.19 $75.01 $106.56 75

5Y P/E Exit $52.91 $84.96 $117.37 70

10Y Revenue Exit $36.96 $56.21 $79.22 67

10Y EBITDA Exit $43.27 $65.55 $92.02 68

10Y P/E Exit $46.82 $72.21 $99.66 64

Earnings-Based

Graham-Dodd $31.37 $63.51 $79.95 66

EPV $40.42 $47.90 $54.45 74

Dividend Discount

Gordon GGM $9.17 $13.31 $17.62 69

DDM Multi-Stage $9.17 $12.95 $17.32 67

Multiples

P/E Multiple $76.12 $101.50 $126.87 63

P/S Multiple $58.82 $78.43 $98.04 58

P/B Multiple $58.82 $78.43 $98.04 55

EV/EBIT $62.30 $84.56 $106.81 66

EV/EBITDA $61.23 $83.12 $105.02 67

EV/Revenue $43.19 $63.61 $84.03 53

Asset-Based

NCAV (Graham) $11.93 $15.99 $23.87 54

Growth DCF

Growth DCF $39.32 $55.39 $77.96 79

Rev-Margin DCF $39.17 $61.59 $85.67 72

Economic Profit

Residual Income $30.36 $40.83 $167.05 64

ROIC Compounder $41.70 $51.53 $61.91 72

Growth Earnings

Growth-Adj P/E $55.21 $78.87 $102.54 67

Widest divergence: Growth Earnings ($78.87) versus Dividend Discount ($12.95). Highest evidence: FCF DCF (80).

Notify me when A reaches fair value

Put A on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 30.1

P/S ratio 5.65 P/E × margin

EPS (TTM) $4.98 price ÷ EPS = P/E 30.1

Dividend yield 0.7% payout 20.2%

Net margin 18.8% FY2025

Return on equity 21.3% TTM

More key figures

Profitability

Return on assets (EBIT) 12.9% avg 5y

Operating margin 23.7% TTM

Growth

Revenue (TTM) $7.2B TTM

Revenue growth (YoY) +10.0% 3y avg +0.5%

EPS growth (YoY) +60.0%

Balance sheet & cash flow

Free cash flow $1.2B FY2025

Net debt $1.6B FY2025 · ≈ 1.4 yrs of FCF

Figures from reported company fundamentals · as of Sep 3, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 70/100

Of which business quality 69 · Market factors (momentum, volatility) 60

Profitability 60

Margins and returns on capital today

Quality Growth 38

Are margins and returns improving?

Cashflow 65

Earnings quality: real cash, not paper profit

Fin. Strength 80

Balance sheet, leverage, solvency risk

Investment 68

Disciplined investing over empire-building

Low Volatility 52

Calm price path (market factor)

Momentum 61

Price trend over the last 3–12 months (market factor)

52W Momentum 69

Distance to the 52-week high (market factor)

Net Issuance 100

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Full company description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Agilent Technologies Inc reported revenue of $6.9B in FY2025 versus $6.3B in FY2021, a compound +2.4%/yr. Reported net income was $1.3B in FY2025, compounding +1.9%/yr from FY2021.

Growth Quality 80/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Latest Revenue (FY 2025)

$6.9B

Latest YoY

+6.7%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+0.5%

Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+5.4%

Avg. revenue growth/yr (27Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

−0.5%

Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.

+7.1% (6.4 + 0.7)

Revenue +2.4%/yr

FY21 $6.3B

FY22 $6.8B

FY23 $6.8B

FY24 $6.5B

FY25 $6.9B

Net income +1.9%/yr

FY21 $1.2B

FY22 $1.3B

FY23 $1.2B

FY24 $1.3B

FY25 $1.3B

Character of growth · EPS growth decomposed (2014-2025) +13.5 % p.a.

Revenue per share +7.4 %

of which total revenue +5.7 % · buybacks/dilution +1.6 %

EBIT margin +5.9 %

Tax rate −0.4 %

Residual (interest, one-offs) +0.1 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

A screens 144% overvalued. Compare with Thermo Fisher Scientific Inc →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Agilent Technologies Inc · Fair Value
$61.53 −144%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/A" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Agilent Technologies Inc · Fair Value</span><br><b style="font-size:20px">$61.53</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−144%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Agilent Technologies Inc Fair Value". https://www.fairvalue-calculator.com/stock/A

Peer Group

Diagnostics & Research · 130 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 70 · Top 25%

Fair Value upside −59% · Below median

Return on equity (TTM) 21% · Top 25%

Return on assets 9% · Top 25%

Net margin (TTM) 20% · Top 25%

Operating margin (TTM) 24% · Top 25%

Revenue growth 10% · Above median

Dividend yield (TTM) 0.7% · Below median

Debt / equity 0.45× · Higher than 75% of peers

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

P/E (TTM) 30.1× · Cheaper than median

P/B 5.51× · Pricier than 75% of peers

P/S (TTM) 5.13× · Pricier than median

P/FCF 32.2× · Pricier than 75% of peers

EV/EBITDA 19.1× · Pricier than median

PEG 1.21× · Cheaper than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE0 · sector 0

FUTURE50 · sector 30

PAST85 · sector 12

HEALTH77 · sector 96

DIVIDEND13 · sector 20

VALUE 0: the price sits above our fair-value range.

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 3, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$630.70	$308.19	−51%
Danaher Corporation DHR	$215.68	$103.88	−52%
WuXi AppTec Co 2359	HK$189.30	HK$150.16	−21%
Lonza Group LONN	CHF 576.60	CHF 259.80	−55%
IDEXX Laboratories, Inc IDXX	$556.69	$255.77	−54%
Waters Corporation WAT	$416.15	$121.96	−71%
IQVIA Holdings IQV	$236.66	$132.17	−44%
Illumina, Inc ILMN	$215.59	$95.51	−56%
Mettler-Toledo International Inc MTD	$1,419	$615.78	−57%
Quest Diagnostics Incorporated DGX	$242.76	$162.50	−33%

Compare Agilent Technologies Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Agilent Technologies Inc (A) overvalued or undervalued?

As of Sep 3, 2026, our model estimates a fair value of $61.53 versus a price of $149.98, about −59% upside (overvalued).

What is the fair value of A?

Our model-based fair value for Agilent Technologies Inc is $61.53 (as of Sep 3, 2026), built from audited fundamentals. The current price: $149.98.

What is the quality score of A?

Agilent Technologies Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the revenue of Agilent Technologies Inc (A)?

Agilent Technologies Inc reported trailing-twelve-month revenue of about $7.2B (latest available figure, as of Sep 3, 2026).

What is the net profit margin of A?

The net profit margin of Agilent Technologies Inc is about 19.6%, meaning it keeps roughly 19.6% of revenue as net income. Based on the latest reported figures.

Does Agilent Technologies Inc pay a dividend?

Agilent Technologies Inc currently shows a dividend yield of about 0.67% relative to its recent price (as of Sep 3, 2026).

Free · no account needed

Watch Agilent Technologies Inc in the live analysis

One click puts Agilent Technologies Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.